DexCom Q1 2024 earnings exceed estimates, with $921M revenue and $0.32 non-GAAP EPS, up 24.2% Y/Y.

DexCom Q1 2024 earnings beat estimates, with non-GAAP EPS of $0.32 and revenue of $921M, up 24.2% Y/Y. Dexcom's FY 2024 guidance for revenue is updated, while Non-GAAP guidance remains unchanged. CEO Kevin Sayer highlighted strategic initiatives and recent highlights during the call, followed by a financial review and outlook from CFO Jereme Sylvain.

April 26, 2024
3 Articles

Further Reading